Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Accumulating evidence suggests that inflammation plays a major role in the pathogenesis of motor neuron death in amyotrophic lateral sclerosis (ALS). Important mediators of inflammation such as the cytokine tumor necrosis factor-α (TNF-α) and its superfamily member fibroblast-associated cell-surface ligand (FasL) have been implicated in apoptosis. We found increased TNF-α and FasL immunoreactivity in lumbar spinal cord sections of ALS patients and G93A transgenic mice. Both increased TNF-α and FasL immunostaining in the lumbar spinal cord of the G93A SOD1 transgenic mice occurred at 40–60 d, well before the onset of symptoms and loss of motor neurons. We tested the neuroprotective effect of thalidomide and its analog lenalidomide, pharmacological agents that inhibit the expression of TNF-α and other cytokines by destabilizing their mRNA. Treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in G93A transgenic mice. Treated G93A mice showed a reduction in TNF-α and FasL immunoreactivity as well as their mRNA in the lumbar spinal cord. Both compounds also reduced interleukin (IL)-12p40, IL-1α, and IL-1β and increased IL-RA and TGF-β1 mRNA. Therefore, both thalidomide and lenalidomide bear promise as therapeutic interventions for the treatment of ALS.

[1]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[2]  R. Dantzer,et al.  A new concept in neurodegeneration: TNFα is a silencer of survival signals , 2000, Trends in Neurosciences.

[3]  J. Julien,et al.  Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis , 2002, Neurobiology of Disease.

[4]  A Hirano,et al.  Neuropathology of ALS , 1996, Neurology.

[5]  D. Green,et al.  Tumor necrosis factor alpha up-regulates non-lymphoid Fas-ligand following superantigen-induced peripheral lymphocyte activation. , 2002, The Journal of biological chemistry.

[6]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. , 1998, Glia.

[7]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .

[8]  V. Dixit,et al.  Recent advances in tumor necrosis factor and CD40 signaling. , 1996, Current opinion in genetics & development.

[9]  M. Beal,et al.  Integrative role of cPLA2 with COX‐2 and the effect of non‐steriodal anti‐inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis , 2005, Journal of neurochemistry.

[10]  A. Imperato,et al.  Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice , 1997, Neuroscience Letters.

[11]  D. Schiffer,et al.  Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis , 1996, Journal of the Neurological Sciences.

[12]  D. Green,et al.  Fas and Fas ligand in gut and liver. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[13]  J. Elliott.  Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. , 2001, Brain research. Molecular brain research.

[14]  M. Beal,et al.  Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis , 2005, Experimental Neurology.

[15]  Minh N. H. Nguyen,et al.  Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: No requirement for proapoptotic interleukin‐1β in neurodegeneration , 2001, Annals of neurology.

[16]  S. Przedborski,et al.  Inducible Nitric Oxide Synthase Up‐Regulation in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1999, Journal of neurochemistry.

[17]  G. Rosoklija,et al.  Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis , 2001, Annals of neurology.

[18]  S. Nagata,et al.  Fas ligand-induced apoptosis. , 1999, Annual review of genetics.

[19]  G. Mora,et al.  Circulating levels of tumour necrosis factor-α and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis , 2000, Neuroscience Letters.

[20]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[21]  T. Siddique,et al.  Molecular genetic basis of familial ALS , 1996, Neurology.

[22]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[23]  B. Pettmann,et al.  Fas/Tumor Necrosis Factor Receptor Death Signaling Is Required for Axotomy-Induced Death of Motoneurons In Vivo , 2003, The Journal of Neuroscience.

[24]  G. Sobue,et al.  Differential expression of inflammation‐ and apoptosis‐related genes in spinal cords of a mutant SOD1 transgenic mouse 
model of familial amyotrophic lateral sclerosis , 2002, Journal of neurochemistry.

[25]  D. Borchelt,et al.  ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions , 1997, Neuron.

[26]  L. Tartaglia,et al.  Two TNF receptors. , 1992, Immunology today.

[27]  K. Hensley,et al.  Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. , 2002, Journal of neurochemistry.

[28]  J. Julien,et al.  Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-α , 2001, The Journal of cell biology.

[29]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[30]  Hiroshi Nishimune,et al.  Motoneuron Death Triggered by a Specific Pathway Downstream of Fas Potentiation by ALS-Linked SOD1 Mutations , 2002, Neuron.

[31]  M. Fresno,et al.  The role of tumour necrosis factor, interleukin 6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system , 1998, Progress in Neurobiology.

[32]  J. Morrison,et al.  Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  E. Feldman,et al.  Neuroinflammation, COX-2, and ALS—a dual role? , 2004, Experimental Neurology.

[34]  P. Ghezzi,et al.  Tumor Necrosis Factor and Motoneuronal Degeneration: An Open Problem , 2002, Neuroimmunomodulation.

[35]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[36]  P. Leigh,et al.  Motor neuron disease. , 1994, Springer London.

[37]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[38]  P. Stieg,et al.  Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. , 2000, Science.

[39]  Angus G. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[40]  D. Borchelt,et al.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.

[41]  M. Bellomo,et al.  Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration. , 1998, European cytokine network.